Literature DB >> 1279838

Comparative characterization of two toxic phospholipases A2 from Indian cobra (Naja naja naja) venom.

B S Basavarajappa1, T V Gowda.   

Abstract

Indian cobra venom contains many phospholipase A2 (PLA2) toxins. In the present study two toxic PLA2s have been purified from the Indian cobra (Naja naja naja) venom by column chromatography. The NN-XIa-and NN-XIb-PLA2s have mol. wts between 10,700 and 15,000. The NN-XIa-PLA2 induces myotoxic effects, oedema and neurotoxicity in mice and has an i.p. LD50 of 8.5 mg/kg body weight. The NN-XIa-PLA2 is also cytotoxic to Ehrlich ascites tumour cells. The other PLA2, NN-XIb, in contrast has an i.p. LD50 of 0.22 mg/kg body weight, and it induces acute neurotoxicity. The NN-XIb-PLA2 is devoid of the other biological activities which are exhibited by NN-XIa-PLA2.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1279838     DOI: 10.1016/0041-0101(92)90439-c

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  4 in total

1.  Strong myotoxic activity of Trimeresurus malabaricus venom: role of metalloproteases.

Authors:  C D Raghavendra Gowda; R Rajesh; A Nataraju; B L Dhananjaya; A R Raghupathi; T V Gowda; B K Sharath; B S Vishwanath
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

Review 2.  Biomedical applications of snake venom: from basic science to autoimmunity and rheumatology.

Authors:  Carlos A Cañas; Santiago Castaño-Valencia; Fernando Castro-Herrera; Felipe Cañas; Gabriel J Tobón
Journal:  J Transl Autoimmun       Date:  2020-12-14

3.  Hypothesis of snake and insect venoms against Human Immunodeficiency Virus: a review.

Authors:  Ramachandran Meenakshisundaram; Shah Sweni; Ponniah Thirumalaikolundusubramanian
Journal:  AIDS Res Ther       Date:  2009-11-19       Impact factor: 2.250

4.  Antitumor effect of Bothrops jararaca venom.

Authors:  Reinaldo J da Silva; Márcia G da Silva; Lízia C Vilela; Denise Fecchio
Journal:  Mediators Inflamm       Date:  2002-04       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.